An Open-Label, Multi-Site Phase 2 Study of the Safety and Effect of Manualized MDMA-Assisted Psychotherapy for the Treatment of Severe Posttraumatic Stress Disorder (United States and Canada)

The MAPS-sponsored Phase 2 open-label lead-in study of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD) is taking place at planned Phase 3 sites across the United States and Canada. The purpose of this study is to provide the final training for our co-therapy teams in preparation for Phase 3 trials. The study will gather supportive data on the safety and effect of manualized MDMA-assisted psychotherapy while providing an opportunity for clinical supervision to planned Phase 3 therapy teams. Each co-therapy team will work with a single participant at their respective study site with supervision provided by MAPS' therapy training team.

Locations:

  • Los Angeles, CA | private practice
  • San Francisco, CA | research institution
  • San Francisco, CA | private practice
  • Boulder, CO | private practice
  • Fort Collins, CO | private practice
  • New Orleans, LA | private practice
  • New York, NY | research institution
  • New York, NY | private practice
  • Charleston, SC | private practice
  • Madison, WI | research institution
  • Boston, MA | private practice
  • Montreal, Canada | private practice
  • Vancouver, Canada | research institution
  • Israel | private practice

Medical Monitor: Michael Mithoefer, M.D.

More information:


Participate: MDMA Studies